{'fraction_non_alphanumeric': 0.05101275318829707, 'fraction_numerical': 0.0277569392348087, 'mean_word_length': 4.8766519823788546, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Combined modality therapy for malignant lymphoma of the primary central nervous system: a preliminary report of a new chemotherapeutic regimen with "PEACE"].

Between 1994 and 1998, a total of 5 patients with primary central nervous system malignant lymphoma (PCNSML) were enrolled in this study. There were one man and four women, with a median age of 53 years. These patients were treated with a new systemic chemotherapeutic regimen "PEACE" therapy. After undergoing surgery (biopsy or resection), the patients received radiotherapy followed by adjuvant chemotherapy with combination of procarbazine (P) (100 mg/day, p.o., day 1 to day 5), cyclophosphamide (E) (200 mg/sqm/day, day 4), doxorubicin hydrochloride (A) (20 mg/sqm/day, day 4 and day 5), carboplatin (C) (300 mg/sqm/day, day 1), and etoposide (E) (30 mg/sqm/day, day 1 to day 3). This regimen was repeated for at least three cycles every 4 to 6 weeks. Intrathecal injection of methotrexate was also administrated in conjunction with systemic chemotherapy except in one case. Complete response was seen in one, and partial response in four patients. Toxicity was tolerable. Median survival time was 31.5 months. The results suggest the efficacy of this chemotherapeutic regimen and further emphasize a role for adjuvant chemotherapy in the initial treatment of PCNSML.